2004
DOI: 10.1200/jco.2004.22.14_suppl.9004
|View full text |Cite
|
Sign up to set email alerts
|

Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
7
0

Year Published

2005
2005
2011
2011

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(8 citation statements)
references
References 0 publications
1
7
0
Order By: Relevance
“…However, in a small group of 68 crossover patients, five patients (7%) demonstrated a partial tumor response, and 20 patients (29%) achieved stable disease with dose escalation to 800 mg/d [27]. Similar findings of improved time to progression on primary treatment with a higher dose or after crossover from 400 mg to 800 mg were also seen in the larger EORTC-ISG-AGITG study [28]. Verweij et al [29•] studied 946 GISTs and reported, at a median follow-up of 760 days, that an imatinib dose of 400 mg twice a day achieves significantly longer progression-free survival.…”
Section: Appropriate Imatinib Dosingsupporting
confidence: 71%
“…However, in a small group of 68 crossover patients, five patients (7%) demonstrated a partial tumor response, and 20 patients (29%) achieved stable disease with dose escalation to 800 mg/d [27]. Similar findings of improved time to progression on primary treatment with a higher dose or after crossover from 400 mg to 800 mg were also seen in the larger EORTC-ISG-AGITG study [28]. Verweij et al [29•] studied 946 GISTs and reported, at a median follow-up of 760 days, that an imatinib dose of 400 mg twice a day achieves significantly longer progression-free survival.…”
Section: Appropriate Imatinib Dosingsupporting
confidence: 71%
“…12,13 However, more prolonged TTP was shown in a limited number of patients with complete resection (Fig. 1B).…”
Section: Discussionmentioning
confidence: 93%
“…10,11 An increase in the imatinib dose (400 to 800 mg/day) was shown to have been effective for 30% of patients (PR, 2.3% and SD, 27.1%), with a median progression-free survival of 81 days and moderate safety. 12 In our series, only three patients had increased to 600 or 800 mg/day, because doses over 400 mg are not approved in Japan. Although the resistant lesions in these patients had been controlled for a few months by the dose increase, in one patient (patient 14), the progressive lesion became a huge mass, and in the other two patients (patients 15 and 16) the number of resistant lesions had increased at surgery, which might result in an incomplete resection in these patients.…”
Section: Discussionmentioning
confidence: 96%
“…These were:EORTC-ISG-AGITG (62005) trial, as reported by Zalcberg and colleagues [17] and Debiec-Rychter and colleagues [24], with one additional abstract reporting interim data [36]. …”
Section: Resultsmentioning
confidence: 99%